Grant Number: 1U01FD005780-01 REVISED
FAIN: U01FD005780

Principal Investigator:
Patrick R Shannon

Project Title: National Antimicrobial Resistance Monitoring System (NARMS)- Surveillance in Retail Food Specimens in Missouri

Mr. Fischer, Bret
Director, Division of Administration
920 Wildwood Drive
PO Box 570
Jefferson City, MO 651020570

Budget Period: 09/01/2016 – 08/31/2017
Project Period: 09/01/2016 – 08/31/2021

Dear Business Official:

The Food and Drug Administration hereby revises this award to reflect an increase in the amount of $124,296 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to MISSOURI STATE DEPT/ HEALTH & SENIOR SRV in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

If you have any questions about this award, please contact the Grants Management Specialist and the Project Officer listed in the terms and conditions.

Sincerely yours,

Kimberly Pendleton
Grants Management Officer
Office of Acquisitions & Grants Services
Division of Acquisition Support and Grants
Grants & Assistance Team
FOOD AND DRUG ADMINISTRATION

See additional information below
SECTION I - AWARD DATA – 1U01FD005780-01 REVISED

Award Calculation (U.S. Dollars)

Other Costs $124,296

Federal Direct Costs $124,296
Approved Budget $124,296
Federal Share $124,296
TOTAL FEDERAL AWARD AMOUNT $124,296

AMOUNT OF THIS ACTION (FEDERAL SHARE) $124,296

<table>
<thead>
<tr>
<th>YR</th>
<th>THIS AWARD</th>
<th>CUMULATIVE TOTALS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$124,296</td>
<td>$124,296</td>
</tr>
<tr>
<td>2</td>
<td>$124,296</td>
<td>$124,296</td>
</tr>
<tr>
<td>3</td>
<td>$124,296</td>
<td>$124,296</td>
</tr>
<tr>
<td>4</td>
<td>$124,296</td>
<td>$124,296</td>
</tr>
<tr>
<td>5</td>
<td>$124,296</td>
<td>$124,296</td>
</tr>
</tbody>
</table>

* Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

Fiscal Information:
CFDA Number: 93.876
EIN: [redacted]
Document Number: UFD005780A
PMS Account Type: P(Subaccount)
Fiscal Year: 2016

<table>
<thead>
<tr>
<th>IC</th>
<th>FD</th>
<th>IC</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>6993016</td>
<td>$124,296</td>
<td>$124,296</td>
<td>$124,296</td>
<td>$124,296</td>
<td>$124,296</td>
</tr>
</tbody>
</table>

* Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

FDA Administrative Data:

SECTION II – PAYMENT/HOTLINE INFORMATION – 1U01FD005780-01 REVISED

Grant payments will be made available through the DHHS Payment Management System (PMS). PMS is administered by the Division of Payment Management, Program Support Center (PSC), DHHS, Office of the Deputy Assistant Secretary, Finance. Requests for downloadable forms and inquiries regarding payment should be directed to:

Regular Mailing Address:
Division of Payment Management
P.O. Box 6021
Rockville, MD 20852
Telephone: (301) 443-1660

Included are the following Links & Instructions for drawing down funds, reporting expenditures, required forms, and the help desk info:
SECTION III – TERMS AND CONDITIONS – 1U01FD005780-01 REVISED

This award is based on the application submitted to, and as approved by, FDA on the above-title project and is subject to the terms and conditions incorporated either directly or by reference in the following:

a. The grant program legislation and program regulation cited in this Notice of Grant Award.
b. The restrictions on the expenditure of federal funds in appropriations acts to the extent those restrictions are pertinent to the award.
c. 45 CFR Part 75.
d. The HHS Grants Policy Statement, including addenda in effect at the beginning date of the budget period.
e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
f. A required Federal Financial Report (FFR) SF-425 must be submitted annually. FDA now requires all annual financial expenditure reports to be submitted electronically using the Federal Financial Report (FFR) system located in the eRA Commons. Annual FFRs must be submitted for each budget period no later than 90 days after the end of the calendar quarter in which the budget period ended. The reporting period for an annual FFR will be that of the budget period for the particular grant; however, the actual submission date is based on the calendar quarter. Failure to submit timely reports may affect future funding.
g. Closeout Requirements (when applicable): A Final Program Progress Activity Report, Final Federal Financial Report SF-425, Final Invention Statement HHS-568 (if applicable), Tangible Personal Property Report SF-428, and Statement of Disposition of Equipment (if applicable) must be submitted within 90 days after the expiration date of the project period.
h. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

This award has been assigned the Federal Award Identification Number (FAIN) U01FD005780. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Treatment of Program Income:
Additional Costs

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than $10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make
semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75.

SECTION IV – FD Special Terms and Condition – 1U01FD005780-01 REVISED

9/9/2016 - This award is being revised to reflect the correct EIN.

*NOTE* ALL TERMS ISSUED ON 08/24/2016 REMAIN IN EFFECT.

9/6/2016 - This award is being revised to correct the EIN.

Financial Reporting:

A. Cash Transaction Reports

The Federal Financial Report (FFR) has a dedicated section to report Federal cash receipts and disbursements. For recipients this information must be submitted quarterly directly to the Payment Management System (PMS) using the web-based tool. Quarterly reports are due 30 days following the end of each calendar quarter. The reporting period for this report continues to be based on the calendar quarter. Questions concerning the requirements for this quarterly financial report should be directed to the PMS.

B. Financial Expenditure Reports

A required Federal Financial Report (FFR) must be submitted annually. FDA now requires all annual financial expenditure reports to be submitted electronically using the Federal Financial Report (FFR) system located in the eRA Commons. This includes all initial FFRs being prepared for submission and any revised FSR/FFRs being submitted or re-submitted to FDA. Paper expenditure/FFR reports will not accepted.

Annual FFRs must be submitted for each budget period no later than 90 days after the end of the calendar quarter in which the budget period ended. The reporting period for an annual FFR will be that of the budget period for the particular grant; however, the actual submission date is based on the calendar quarter. Failure to submit timely reports may affect future funding.

Performance Progress Reporting:

1. Annual progress reports are required. The Annual Progress Report will be due as part of the Research Performance Progress Report (RPPR).

2. Grants with Multiple Years: When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR).

SPECIAL TERMS AND CONDITIONS

The following conditions of the award will apply to all funded applicants and must be maintained throughout the cooperative agreement; these conditions include, but are not limited, to those listed below:

Page-4
1. Actively participate in NARMS conference calls and working groups

2. Implement NARMS sampling and laboratory protocols to ensure standardized methodologies

3. Implement standardized data collection and isolate transmission protocols

4. Provide FDA with a list of sampling areas that meet the NARMS sampling requirements

5. Collect fresh retail meat at a minimum of 2 non-consecutive days per month from pre-selected retail locations

6. Perform microbiological tests on retail meat samples according to the final application accepted by FDA

7. Participate in NARMS pilot studies to examine novel fresh retail meat samples or to assess resistance in other organisms as specified in ad hoc pilot studies

8. Provide serotype and/or species identifications for isolates when available

9. Send isolates to the FDA on a monthly basis for antimicrobial susceptibility testing and other analyses.

Specific activities that are NOT supported by this cooperative agreement include but are not limited to those listed below:

1. Molecular testing of isolates cultured from fresh retail meat/food for the NARMS program

2. Collection and testing of meats and/or food products not specified in the sampling assignment

3. Isolation of organisms other than those agreed to or specified in pilot study programs

FDA staff is substantially involved in the NARMS retail food surveillance program activities beyond routine grant monitoring which include but are not limited to the activities listed below:

1. Provide general coordination for all NARMS retail food surveillance sites and the overall NARMS network

2. Develop, facilitate, and participate in collaborative multi-site relationships as needed to support the successful completion of the program activities

3. Provide scientific consultation and technical assistance as necessary in the operation of the NARMS retail food surveillance program

4. Facilitate the development of protocols, procedure manuals, and training of applicants

5. Perform confirmatory bacterial identifications and antimicrobial susceptibility testing

6. Perform whole genome sequencing and other molecular characterization of NARMS isolates

7. Analyze, interpret, and disseminate surveillance results.

8. Any presentation of the results of testing must undergo FDA Office of Research and Center review and approval process. This process can take 30-90 days.

9. Coordinating and facilitating communications among NARMS retail food surveillance sites.
FAILURE TO COMPLY WITH THE ABOVE STATE TERMS AND CONDITIONS COULD RESULT IN THE SUSPENSION OR TERMINATION OF THIS COOPERATIVE AGREEMENT.

All formal correspondence/reports regarding the grant should be signed by an authorized institutional official and the Principal Investigator and should be sent to the attention of the grants management specialist, unless otherwise directed.

For inquiries regarding scientific programmatic issues and fiscal and/or administrative matters please refer to STAFF CONTACTS listed below:

Project Officer: Patrick McDermott
Email: patrick.mcdermott@fda.hhs.gov / Phone (240) 402-0891

Grants Management Specialist: Bryce Jones
Email: Bryce.Jones@fda.hhs.gov / Phone (240) 402-2111

Direct inquiries regarding scientific programmatic issues to the official listed below.

Direct inquiries regarding fiscal and/or administrative matters to the grants management specialist listed below.

All formal correspondence/reports regarding the grant should be signed by an authorized institutional official and the Principal Investigator and should be sent to the attention of the grants management specialist, unless otherwise explicitly directed.

STAFF CONTACTS
Grants Management Specialist: Bryce Jones
Email: bryce.jones@fda.hhs.gov Phone: 240-402-2111

SPREADSHEET SUMMARY
GRANT NUMBER: 1U01FD005780-01 REVISED

INSTITUTION: MISSOURI STATE DEPT/ HEALTH & SENIOR SRV

<table>
<thead>
<tr>
<th>Budget</th>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
<th>Year 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Costs</td>
<td>$124,296</td>
<td>$124,296</td>
<td>$124,296</td>
<td>$124,296</td>
<td>$124,296</td>
</tr>
<tr>
<td>TOTAL FEDERAL DC</td>
<td>$124,296</td>
<td>$124,296</td>
<td>$124,296</td>
<td>$124,296</td>
<td>$124,296</td>
</tr>
<tr>
<td>TOTAL FEDERAL F&amp;A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL COST</td>
<td>$124,296</td>
<td>$124,296</td>
<td>$124,296</td>
<td>$124,296</td>
<td>$124,296</td>
</tr>
</tbody>
</table>